Other

Xoma Corporation

Xdx, Inc.

Genentech, Inc.

Russell L Dedrick

Marvin R Garovoy

Susan Kramer

Karen Starko

Kirk E Fry

Stephen Fitzhugh Carroll

Preeti G Lal

Steven Rosenberg

Bin Wu

Gavin E Williams

Jingtao Sun

The invention presents a method of diagnosing or monitoring the status of systemic lupus erythematosus (SLE) in a subject or patient comprising detecting the expression of all genes of a diagnostic set in the subject or patient wherein the diagnostic set comprises two or more genes having expression correlated with the classification or status of SLE; and diagnosing or monitoring the status of SLE in the subject or patient by applying at least one statistical method to the expression of the genes of the diagnostic set.

Methods for diagnosing and monitoring the status of systemic lupus erythematosus

The invention presents methods of using splice variants and reagents thereof for diagnosing and monitoring the status of transplants and immune disorders including diagnosing, monitoring and predicting transplant rejection or non-rejection, steroid responsiveness, and onset or flare of immune disorders.

Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders

A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.

Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist

A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need therof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.

Treatment method

Novel LBP compositions and therapeutic uses for LBP are provided for preventing the adverse effects of exposure to endotoxin.

Uses of lipopolysaccharide binding protein

Growing community of inventors

Kensington, CA, United States of America

Russell L Dedrick